Articles by Charlotte Robinson
Tonix Pharmaceuticals and Makana Therapeutics will collaborate on preclinical xenotransplantation research and development.
The FDA has granted Priority Review to pegcetacoplan to treat C3 glomerulopathy and primary IC-MPGN.
Dr. Thomas Pham spoke to us about kidney donation during National Donate Life Month.
The National Kidney Foundation (NKF) announced the Spring Clinical Meetings 2025 (SCM25) Outstanding Poster honorees.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Research compared the effects of sparsentan and irbesartan on proteinuria remission in focal segmental glomerulosclerosis.
A study compared kidney stone formation with the use of chlorthalidone vs hydrochlorothiazide for hypertension.
Researchers examined factors associated with adherence to the urate-lowering therapy allopurinol.
A study examined one medical center's adherence to gout management guidelines regarding use of ULT to lower uric acid levels.
A study examined whether systemic inflammation response index could be a predictive marker for gout risk.
Researchers assessed how prescription rates of SGLT2i were affected when DKD risk was predicted by a KidneyIntelX test.
A partnership will provide education to primary care clinicians to strengthen identification and treatment of kidney disease.
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
Researchers in China announced that they have performed a successful transplant of a gene-edited pig kidney into a patient.
Research examined the efficacy and safety of lumasiran for primary hyperoxaluria type 1 in infants and toddlers.
Suphamai Bunnapradist discussed the phase 3 TRANSCEND study of felzartamab to treat late AMR after kidney transplantation.
Dosing calculations for carboplatin made using Cockcroft-Gault creatinine clearance may result in excess dosing.
A study explored the association between SCr/CYS ratio and adverse events associated with platinum-based cancer therapies.
Faith Lynch, president-elect of ANNA, discussed her upcoming term and challenges faced by nephrology nurses.
Impaired kidney function was the primary predictor of hemorrhage among patients treated with anticoagulant apixaban.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.